Acute Myeloid Leukemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.
View More
Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.
View More
Dr Maiti discusses findings from a trial of 10-day decitabine plus venetoclax for patients with newly diagnosed, intensive chemo–ineligible, and relapsed/refractory AML.
View More
Dr Percival provides her insight on how the treatment landscape has evolved thus far for patients with AML, and therapies that are currently in the pipeline.
View More
Amer Zeidan, MBBS, discusses a trial exploring onvansertinib plus standard-of-care chemo in patients with AML.
View More
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
View More
Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.
View More
Courtney DiNardo, MD, MSCE, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated AML.
View More
Naval Daver, MD, discusses the results of a phase 2 study exploring azacitidine plus nivolumab and ipilimumab for patients with relapsed/refractory AML.
View More
Stay in the know.
OncNet Newsletter